NIFTY  9,360.55  -0.27%
  SENSEX  30,301.60  -0.21%
 CURRENCY  Rs  64.89/$ 72.59/€, 84.18/£
  GOLD  28,710.00  -0.35%
  SILVER  39,830.00  -0.32%
  DAX  12,642.90  -0.13%
  FTSE  7,514.90  0.40%
  CAC  5,341.34  -0.11%
  HANG SENG  25,428.50  0.10%
  NIKKEI  19,743.00  0.66%
  Shanghai Composite  3,064.08  0.03%
  DOW JONES  21,012.40  0.36%
  NASDAQ  6,163.02  0.40%
  S&P 500  2,404.39  0.25%
SOURCES TO COGENCIES : Cabinet Approves Proposal For Abolition Of Foreign Investment Promotion Board SOURCES TO COGENCIES : Cabinet Approves Proposal On 2017-18 Sugarcane Prices SOURCES TO COGENCIES : Need For Cabinet Nod For FDI Over Rs 5000 Cr To Remain TATA INVEST Q4 EARNINGS : PAT Rs 16.1 Cr Vs Rs 22.3 Cr YoY TATA INVEST Q4 EARNINGS : Revenue Rs 35.8 Cr Vs Rs 32.3 Cr YoY TATA INVEST Q4 EARNINGS : To Pay Dividend Of Rs 18/Share PRASUN GAJRI HDFC LIFE : I.T. Stocks May Perform Better On A Short-Term Basis FROM REUTERS : KOC & Tata Group Sign Joint Venture To Tap Into White Goods Consumer Market

Ranbaxy Q4: Co Allays U.S. FDA Fears

Video:

Play this video

February 5: Ranbaxy's fourth quarter revenues and margins have come in-line with street estimates. Also, commentary from the management on the U.S. FDA ban at Toansa has boosted the stock. The management allayed fears regarding the U.S. FDA ban on their Toansa facility. Agam Vakil and Priya Sheth share more details on the company’s Q4 results and the management commentary.